P-057 Myelodysplastic syndromes (MDS) with a deletion 5q display a specific immunophenotypic profile

Uta Oelschlaegel(University Hospital Carl Gustav Carus), Uwe Platzbecker(National Center for Tumor Diseases), Martin Bornhäuser(Technische Universität Dresden), T.M. Westers, Katja Sockel(Innsbruck Medical University), S. Parmentier(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Brigitte Mohr(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Arjan A. van de Loosdrecht(Dutch Cancer Society)
Leukemia Research
May 1, 2013
10.1016/s0145-2126(13)70106-1
Cited by 0

Related Papers

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis
|JAMA|2014|739
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633